Human Albumin CSL Behring, 200 g/l, solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

human albumin csl behring, 200 g/l, solution for infusion

csl behring gmbh - human albumin solution - solution for infusion - 20, 200 gram(s)/litre - albumin

Human Albumin Solution for Infusion 20% Behring Singapore - English - HSA (Health Sciences Authority)

human albumin solution for infusion 20% behring

csl behring pte. ltd. - human albumin - infusion, solution - 200g/l - human albumin 200g/l

Water for Injections CSL Behring solvent for parental use Malta - English - Medicines Authority

water for injections csl behring solvent for parental use

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - water for, injection - solvent for parenteral use - water for injection - all other non-therapeutic products

HUMAN ALBUMIN 20% BEHRING Israel - English - Ministry of Health

human albumin 20% behring

csl behring ltd., israel - albumin human - solution for infusion - albumin human 200 mg/ml - albumin - albumin - hypoalbuminemia (liver cirrhosis nephrosis) toxic processes ( pregnancy toxicosis, hyperbilirubinemia ) ,volume substitution therapy.

BERINERT Israel - English - Ministry of Health

berinert

csl behring ltd., israel - c - 1 esterase inhibitor human - powder for solution for inj/inf - c - 1 esterase inhibitor human 500 iu/vial - c1- inhibitor,plasma derived - c1- inhibitor,plasma derived - hereditary angioedema type i and ii (hae).treatment and pre-procedure (prior to oral, dental, and upper respiratory tract procedures) prevention of acute episodes

Respreeza European Union - English - EMA (European Medicines Agency)

respreeza

csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,

Cluvot 250 IU, powder and solvent for solution for injection/infusion Malta - English - Medicines Authority

cluvot 250 iu, powder and solvent for solution for injection/infusion

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - human coagulation, factor xiii - powder and solvent for solution for infusion or injection - human coagulation factor xiii 250 iu - antihemorrhagics

Cluvot 1250 IU, powder and solvent for solution for injection/infusion Malta - English - Medicines Authority

cluvot 1250 iu, powder and solvent for solution for injection/infusion

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - human coagulation, factor xiii - powder and solvent for solution for infusion or injection - human coagulation factor xiii 1250 iu - antihemorrhagics

Rhophylac  300mcg/2ml Solution for Injection in pre-filled syringe Malta - English - Medicines Authority

rhophylac 300mcg/2ml solution for injection in pre-filled syringe

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - anti, d immunoglobulin, human - solution for injection in a pre-filled syringe - anti-d immunoglobulin, human 150 µg/ml - immune sera and immunoglobulins

Riastap 1 g Powder for solution for injection / infusion Malta - English - Medicines Authority

riastap 1 g powder for solution for injection / infusion

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - human fibrinogen - powder for solution for injection/infusion - human fibrinogen 1 g - antihemorrhagics